LakeShore Biopharma (LSB) Competitors $0.53 -0.26 (-32.95%) Closing price 09/19/2025Extended Trading$0.53 0.00 (0.00%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. SLGL, QNTM, ANL, HYPD, CVM, HOWL, VTVT, INKT, ADVM, and CLNNShould you be buying LakeShore Biopharma stock or one of its competitors? The main competitors of LakeShore Biopharma include Sol-Gel Technologies (SLGL), Quantum Biopharma (QNTM), Adlai Nortye (ANL), Hyperion DeFi (HYPD), CEL-SCI (CVM), Werewolf Therapeutics (HOWL), vTv Therapeutics (VTVT), MiNK Therapeutics (INKT), Adverum Biotechnologies (ADVM), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. LakeShore Biopharma vs. Its Competitors Sol-Gel Technologies Quantum Biopharma Adlai Nortye Hyperion DeFi CEL-SCI Werewolf Therapeutics vTv Therapeutics MiNK Therapeutics Adverum Biotechnologies Clene Sol-Gel Technologies (NASDAQ:SLGL) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment. Which has preferable earnings and valuation, SLGL or LSB? Sol-Gel Technologies has higher earnings, but lower revenue than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$11.54M6.79-$10.58M-$1.23-22.82LakeShore Biopharma$85.67M0.13-$13.93MN/AN/A Is SLGL or LSB more profitable? LakeShore Biopharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -14.25%. LakeShore Biopharma's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-14.25% -11.80% -9.39% LakeShore Biopharma N/A N/A N/A Do insiders & institutionals hold more shares of SLGL or LSB? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, SLGL or LSB? Sol-Gel Technologies has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Does the media prefer SLGL or LSB? In the previous week, LakeShore Biopharma had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 2 mentions for LakeShore Biopharma and 1 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.89 beat LakeShore Biopharma's score of 0.95 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Overall Sentiment Sol-Gel Technologies Very Positive LakeShore Biopharma Positive SummaryLakeShore Biopharma beats Sol-Gel Technologies on 6 of the 11 factors compared between the two stocks. Get LakeShore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeShore BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.01M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E RatioN/A20.6375.7726.11Price / Sales0.13442.69544.62124.93Price / CashN/A44.6737.5461.24Price / Book0.169.6212.876.30Net Income-$13.93M-$52.73M$3.29B$271.03M7 Day Performance-15.47%1.81%0.28%-0.14%1 Month Performance-34.80%5.50%2.87%5.82%1 Year Performance-93.19%18.12%65.66%27.63% LakeShore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeShore Biopharma1.1669 of 5 stars$0.53-33.0%N/A-93.1%$11.01M$85.67M0.00773High Trading VolumeSLGLSol-Gel Technologies0.5654 of 5 stars$23.90-0.4%N/A+298.6%$66.80M$11.54M-19.4350QNTMQuantum Biopharma0.4521 of 5 stars$16.65-4.3%N/A+349.2%$66.40MN/A-1.19N/AANLAdlai Nortye1.9313 of 5 stars$1.79flat$9.00+402.8%-17.6%$66.05M$5M0.00127Positive NewsHYPDHyperion DeFi0.4603 of 5 stars$11.55-0.1%$2.00-82.7%-77.3%$65.83M$60K-0.2040News CoverageGap DownHigh Trading VolumeCVMCEL-SCI1.4668 of 5 stars$9.52-3.5%N/A-73.0%$65.52MN/A-19.8343Positive NewsHOWLWerewolf Therapeutics3.6801 of 5 stars$1.45+1.4%$8.00+451.7%+1.0%$65.39M$1.88M-0.8840VTVTvTv Therapeutics2.4111 of 5 stars$21.43+5.0%$35.50+65.7%+71.2%$65.20M$1.02M-6.879INKTMiNK Therapeutics3.4454 of 5 stars$14.59+2.2%$37.50+157.0%+79.1%$64.54MN/A-5.0730Gap UpADVMAdverum Biotechnologies3.6821 of 5 stars$3.02-1.6%$19.75+554.0%-34.6%$64.42M$1M-0.38190Analyst ForecastCLNNClene3.1622 of 5 stars$6.33+1.3%$32.60+415.0%+26.2%$62.94M$340K-1.68100News CoverageAnalyst Forecast Related Companies and Tools Related Companies Sol-Gel Technologies Competitors Quantum Biopharma Competitors Adlai Nortye Competitors Hyperion DeFi Competitors CEL-SCI Competitors Werewolf Therapeutics Competitors vTv Therapeutics Competitors MiNK Therapeutics Competitors Adverum Biotechnologies Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LakeShore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share LakeShore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
